Study #2021-0044
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to Pembrolizumab
MD Anderson Study Status
Not Accepting
Treatment Agent
Combination Product: LTX-315 in combination with pembrolizumab
Description
ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have either exhausted treatment options or are not eligible for, suitable for, or willing to undergo such treatments.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Melanoma
Study phase:
Phase II
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.